The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...
Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...
TipRanks on MSN
Vertex price target lowered to $23 from $29 at DA Davidson
DA Davidson analyst Gil Luria lowered the firm’s price target on Vertex (VERX) to $23 from $29 and keeps a Neutral rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback